Sitagliptin phosphate ine(Oxedrine) this results in the proteasomal

this results in the proteasomal degradation of oncogenic client proteins

100 mg/kg Moxifloxacin in mice gives activity comparable to INH

Fluzoparib acts synergistically to inhibit cell growth and promote apoptosis among lung cancer cells

BDBM50001450

Sitagliptin phosphate ine(Oxedrine) this results in the proteasomalSitagliptin (INN; previously identified as MK 0431 and sold under the trade name Januvia) is an oral antihyperglycemic (anti diabetic drug) of the dipeptidyl peptidase 4 (DPP 4) inhibitor class. It was developed and is marketed by Merck & Co. This enzyme inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. The benefit of